Rare Disease Product Revenue — Total Revenue
Biogen Rare Disease Product Revenue — Total Revenue increased by 8.3% to $557.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.1%, from $563.30M to $557.20M. Over 4 years (FY 2021 to FY 2025), Rare Disease Product Revenue — Total Revenue shows an upward trend with a 3.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration and adoption of rare disease therapies, while a decrease may signal competitive pressure, patent expirations, or challenges in patient access and reimbursement.
Detailed definition
This metric represents the total gross revenue generated from the sale of pharmaceutical products specifically indicated...
Peer comparison
Comparable to orphan drug revenue segments reported by other large-cap biopharmaceutical companies, often evaluated based on the size of the addressable patient population and the exclusivity period of the therapies.
biib_segment_rare_disease_product_revenue_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $476.28M | $476.28M | $476.28M | $448.38M | $448.38M | $448.38M | $448.38M | $443.30M | $438.00M | $449.90M | $471.80M | $423.90M | $534.10M | $494.80M | $535.30M | $563.30M | $543.00M | $533.30M | $514.60M | $557.20M |
| QoQ Change | — | +0.0% | +0.0% | -5.9% | +0.0% | +0.0% | +0.0% | -1.1% | -1.2% | +2.7% | +4.9% | -10.2% | +26.0% | -7.4% | +8.2% | +5.2% | -3.6% | -1.8% | -3.5% | +8.3% |
| YoY Change | — | — | — | — | -5.9% | -5.9% | -5.9% | -1.1% | -2.3% | +0.3% | +5.2% | -4.4% | +21.9% | +10.0% | +13.5% | +32.9% | +1.7% | +7.8% | -3.9% | -1.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's rare disease product revenue — total revenue?
- Biogen (BIIB) reported rare disease product revenue — total revenue of $557.20M in Q1 2026.
- How has Biogen's rare disease product revenue — total revenue changed year-over-year?
- Biogen's rare disease product revenue — total revenue decreased by 1.1% year-over-year, from $563.30M to $557.20M.
- What is the long-term trend for Biogen's rare disease product revenue — total revenue?
- Over 4 years (2021 to 2025), Biogen's rare disease product revenue — total revenue has grown at a 3.1% compound annual growth rate (CAGR), from $1.91B to $2.15B.
- What does rare disease product revenue — total revenue mean?
- The total sales revenue generated from pharmaceutical products designed to treat rare diseases.